Isconova’s partner Genocea Biosciences unveils data on their Herpes Simplex Virus type 2 vaccine containing Isconova’s adjuvant Matrix-M™
The preclinical data will be presented this week at the 37th annual International Herpesvirus Workshop (IHW) in Calgary, Canada. Additional information is available on Genocea’s website.
For more information, please follow the link below:
Karin Lövgren, CSO
Tel.: +46 (0) 18- 16 17 07
TO THE EDITORS
Isconova AB is a leading international vaccine adjuvant company. Isconova has extensive knowledge of vaccine systems, and develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconova’s nano-particle Matrix™ technology, Equilis®Prequenza, was launched on the veterinary market in 2006. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix-M™. Isconova’s partners include Crucell/J&J, Pfizer, Merck & Co., The Jenner Institute and Genocea. The Company is headquartered in Uppsala, Sweden.
Isconova AB is listed on NASDAQ OMX First North (ticker: ISCO).
About Genocea Biosciences
Genocea is a US research and development company founded in 2006 in Cambridge, USA. The company has received great attention for their progress in vaccine development and was named “One of the World’s Most Intriguing Startups” in 2009 by Businessweek.
Genocea is developing a new class of human vaccines based on a revolutionary platform for the rapid discovery of antigens that induce T cell immunity.
Matrix-M™ is a nano-particulate, saponin-based adjuvant, developed and produced by Isconova AB. The adjuvant is a potent inducer of well balanced Th1 and Th2 type of immune responses promoting humoral and cellular immunity
Adjuvants enhance the efficacy of a vaccine or drugs while maintaining safety. Adjuvants increase the vaccine’s ability to produce antibodies and induce a cellular response that is important for modern vaccines.